Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Initiative in Chemical Biology and Therapeutics
The Department of Biotechnology (DBT) of the Government of India will fund a new initiative for chemical biology and molecular therapeutics in Bangalore at the Institute for Stem Cell Biology and Regenerative Medicine (inStem) in collaboration with the National Centre for Biological Sciences (NCBS), Tata Institute of Fundamental Research. Support from multiple sources including the DBT will provide approximately INR 940M (GBP 10.5M) to establish the initiative.

Researchers in the initiative will combine methods from genetics, chemistry, cell biology, biochemistry and imaging to understand the alterations in cellular systems that underlie human diseases, and identify ways to correct them using drugs. The initiative is expected to develop powerful new scientific approaches for the treatment of diseases like cancer, integrating expertise from the basic and clinical sciences in India. It will create a multidisciplinary environment for training young researchers and physicians in the translation of fundamental research to clinical application. The new initiative is the result of a collaboration that links Professors S. Ramaswamy, K. VijayRaghavan, Satyajit Mayor and colleagues at inStem and NCBS in Bangalore, with Professor Ashok Venkitaraman at the University of Cambridge in the UK. The initiative began in September 2011 when Cambridge University’s Vice-Chancellor Professor Sir Leszek Borysiewicz signed a memorandum of understanding with the inStem and NCBS. The inStem governing council is chaired by Dr. M.K. Bhan, the Secretary, Department of Biotechnology, Government of India.

Professor Ashok Venkitaraman, who is the Ursula Zoellner Professor of Cancer Research, University of Cambridge and Director, Medical Research Council Cancer Cell Unit, says: “Having originally trained and practiced as a physician in India, I am delighted that the Department of Biotechnology, Government of India will be supporting this exciting new initiative. The excellence of my colleagues in Bangalore, and the terrific research environment they have created, inspires confidence that we can work together not only to improve our fundamental understanding of the cellular abnormalities that cause human diseases like cancer but also to translate this information for the benefit of patients.”

Professor K. VijayRaghavan, Acting Director of inStem and the Director of the National Centre for Biological Sciences (NCBS) of the Tata Institute of Fundamental Research (TIFR) says: “inStem is taking a new and adventurous path of collaborative, team-driven efforts to address the most challenging of biomedical problems. The NCBS-inStem campus provides an ideal intellectual environment for this collaboration with Cambridge to succeed. Ashok Venkitaraman is a world-leader in his area and we are delighted to work with him and Sir Leszek, also a leading biomedical researcher and former head of the UK Medical Research Council. inStem is committed to the success of this joint program, approved enthusiastically by its governing council and its Chair, Dr. M. K. Bhan, Secretary, Department of Biotechnology.”

Sir Leszek pointed out that “Cambridge and the Tata Institute, of which NCBS is a part, have a long history of connections. TIFR’s founder Homi Bhabha studied and worked in Cambridge as have many NCBS and inStem faculty. We view this very important collaboration as mutually beneficial and an example of how the best in basic research can address important biomedical questions.”


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.